2 recruiting, 1 completed, 1 terminated, 1 withdrawn. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 2, Completed 1 |
| Phase 2 | 2 | Terminated 1, Withdrawn 1 |
Follow Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm: new trials by email Literature Review of Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm trials Research Report on Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Q702 for the Treatment of Patients With Hematologic Malignancies Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration - Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma | Phase 1 | Recruiting | Mayo Clinic | 46 | 2025-08-27 | 2025-10-10 |
| Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies Acetaminophen, Dexamethasone, Diphenhydramine - Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Completed | City of Hope Medical Center | 13 | 2020-11-18 | 2026-01-28 |
| Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Anti-CD123/CD3 Monoclonal Antibody MGD006 - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Withdrawn | City of Hope Medical Center | 2020-10-20 | 2020-12-17 | |
| HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR, Bone Marrow Aspiration, Biospecimen Collection - Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 24 | 2018-02-23 | 2026-05-18 |
| Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome Decitabine, Laboratory Biomarker Analysis, Venetoclax - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Terminated | M.D. Anderson Cancer Center | 235 | 2018-01-18 | 2026-03-10 |
Blastic Plasmacytoid Dendritic Cell Neoplasm (5) · Leukemia, Biphenotypic, Acute (3) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (3) · Leukemia, Myelomonocytic, Chronic (3) · Myelodysplastic Syndromes (3) · Hematologic Neoplasms (2) · Hodgkin Disease (2) · Leukemia, Hairy Cell (2) · Leukemia, Myeloid, Acute (2) · Mastocytosis, Systemic (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Blast Crisis (1) · Burkitt Lymphoma (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Erdheim-Chester Disease (1)
Bone Marrow Diseases (5) · Chronic Disease (5) · Disease Attributes (5) · Hematologic Diseases (5) · Hemic and Lymphatic Diseases (5) · Histiocytic Disorders, Malignant (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Leukemia, Lymphoid (5) · Leukemia, Myeloid (5) · Lymphatic Diseases (5) · Lymphoma (5) · Lymphoproliferative Disorders (5) · Neoplasms (5) · Neoplasms by Histologic Type (5)
Acetaminophen (1) · Biopsy (1) · Calcium Dobesilate (1) · Decitabine (1) · Dexamethasone (1) · Diphenhydramine (1) · Ibuprofen (1) · Injections (1) · Magnetic Resonance Spectroscopy (1) · Ranitidine (1) · Specimen Handling (1) · auricularum (1) · dexamethasone 21-phosphate (1) · dexamethasone acetate (1) · venetoclax (1)
City of Hope Medical Center (2) · Fred Hutchinson Cancer Center (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1)
United States (4)
Abhishek Maiti, MBBS (1) · Elizabeth Krakow (1) · Ibrahim Aldoss, MD (1) · Ibrahim T Aldoss (1) · Jithma P. Abeykoon, MD (1)
PMID 32896301, PMID 33027528, PMID 33580980, PMID 33792630, PMID 34255353, PMID 34474640, PMID 35622074, PMID 38683966
P30CA033572 (1)